null

Anti-Mouse PD-1 [RMP1-30] In Vivo Antibody - Low Endotoxin (IVMB0338)

SKU:
IVMB0338
Antibody Type:
Functional-Grade In Vivo Antibody
Disease Area:
Cancer Immunotherapy
Disease Area:
Autoimmune Diseases
Clone:
RMP1-30
Protein:
CD279
Isotype:
IgG2b k
Reactivity:
Mouse
Synonyms:
Programmed Death-1
CD279
Research Area:
Immunology
Endotoxin Level:
Low Endotoxin
Host Species:
Rat
Applications:
FC
In Vivo
€289 - €4,859

Description

Product Name:Anti-Mouse PD-1 (Clone RMP1-30) In Vivo Antibody - Low Endotoxin
Product Code:IVMB0338
Size:0.5 mg
Clone:RMP1-30
Protein:CD279
Product Type:Monoclonal Antibody
Synonyms:Programmed Death-1, CD279
Isotype:IgG2b k
Reactivity:Mouse
Applications:FC, In Vivo
Formulation:This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:<1.0 EU/µg as determined by the LAL method
Purity:≥95% monomer by analytical SEC â‹… >95% by SDS Page
Product Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:FC, In Vivo
Reactivity:Mouse
Host Species:Rat
Specificity:RMP1-30 activity is directed against mouse PD-1 (CD279).
Antigen Distribution:PD-1 is expressed on activated T cells, B cells, a subset of thymocytes, macrophages, dendritic cells, and some tumor cells.
Immunogen:Mouse PD-1 transfected BHK cells
Concentration:≥ 5.0 mg/ml
Endotoxin Level:<1.0 EU/µg as determined by the LAL method
Formulation:This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:≥95% monomer by analytical SEC â‹… >95% by SDS Page
Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

PD-1, a member of the CD28/CTLA-4 subfamily of the Ig superfamily, is a transmembrane protein expressed on activated T cells, B cells, a subset of thymocytes, macrophages, dendritic cells, and some tumor cells1,2. PD-1 is also retained in the intracellular compartments of human and mouse regulatory T cells (Tregs) and is co-expressed with CD25 on activated CD4+ T cells3. When stimulated via the T cell receptor (TCR), Tregs translocate PD-1 to the cell surface3. PD-1 is absent on naïve T cells and is inducibly expressed on T cells by T cell antigen receptor (TCR). B7-H1 (PD-L1; CD274) and B7-DC (PD-L2; CD273) have been identified as PD-1 ligands1. PD-1 is co-expressed with PD-L1 on tumor cells and tumor-infiltrating antigen-presenting cells (APCs)2.

PD-1 acts as a T cell inhibitory receptor and plays a critical role in peripheral tolerance induction and autoimmune disease prevention as well as important roles in the survival of dendritic cells, macrophage phagocytosis, and tumor cell glycolysis2. PD-1 prevents uncontrolled T cell activity, leading to attenuation of T cell proliferation, cytokine production, and cytolytic activities. Additionally, the PD-1 pathway, consisting of PD-1 on T cells and PD-L1 on APCs, is a major mechanism of tumor immune evasion, and, as such, PD-1 is a target of cancer immunotherapy2.

RMP1-30 does not block the binding of B7-H1 or B7-DC to PD-11.

Protein:CD279
Research Area:Immunology
Shipping:2-8°C
NCBI Gene Bank ID:18566

Related Products